[go: up one dir, main page]

PE20081464A1 - Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine - Google Patents

Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine

Info

Publication number
PE20081464A1
PE20081464A1 PE2007001409A PE2007001409A PE20081464A1 PE 20081464 A1 PE20081464 A1 PE 20081464A1 PE 2007001409 A PE2007001409 A PE 2007001409A PE 2007001409 A PE2007001409 A PE 2007001409A PE 20081464 A1 PE20081464 A1 PE 20081464A1
Authority
PE
Peru
Prior art keywords
modified release
presents
nsaid
pharmaceutical composition
meloxicam
Prior art date
Application number
PE2007001409A
Other languages
English (en)
Inventor
Lopez Enrique Raul Garcia-Salgado
Paniagua Angelica Arzola
Lopez Luis Fernando Poot
Rodriguez Francisco Escocia
Hernandez Gustavo Barrnco
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of PE20081464A1 publication Critical patent/PE20081464A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIBERACION MODIFICADA EN CAPSULAS CON MICROESFERAS RECUBIERTAS QUE COMPRENDE a) NUCLEOS INERTES RECUBIERTOS CON UNA PRIMERA PELICULA FORMADA POR UN FARMACO MUSCULO RELAJANTE TAL COMO TIZANIDINA; AL MENOS UN POLIMERO ADHESIVO Y UN AGENTE PLASTIFICANTE; b) UNA SEGUNDA PELICULA POLIMERICA RETARDANTE DE AL MENOS UN AGENTE PLASTIFICANTE Y SOLUCION REGULADORA; Y c) UNA TERCERA PELICULA FORMADO POR UN AINE TAL COMO MELOXICAM; TIAZINIDINA; AL MENOS UN POLIMERO ADHESIVO; UN AGENTE PLASTIFICANTE Y UN TENSOACTIVO; DONDE EL FARMACO TIZANDINA PRESENTA LIBERACION MODIFICADA Y EL MELOXICAM PRESENTA LIBERACION INMEDIATA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. ESTA COMPOSICION PRESENTA UNA ACTIVIDAD TERAPEUTICA SINERGICA INDICADA PARA EL TRATAMIENTO DE ESPASTICIDAD, PADECIMIENTOS MUSCULARES Y/O MUSCULO ESQUELETICOS Y DOLOR GENERAL DE MODERADO A SEVERO
PE2007001409A 2006-10-18 2007-10-18 Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine PE20081464A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA06012024 2006-10-18

Publications (1)

Publication Number Publication Date
PE20081464A1 true PE20081464A1 (es) 2008-12-31

Family

ID=39313650

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001409A PE20081464A1 (es) 2006-10-18 2007-10-18 Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine

Country Status (16)

Country Link
US (1) US20100166856A1 (es)
EP (1) EP2085076B1 (es)
AR (1) AR073435A1 (es)
AT (1) ATE499089T1 (es)
BR (1) BRPI0718368A2 (es)
CA (1) CA2670690C (es)
CL (1) CL2007002975A1 (es)
CO (1) CO6140021A2 (es)
CR (1) CR10801A (es)
DE (1) DE602007012751D1 (es)
EC (1) ECSP099348A (es)
ES (1) ES2361883T3 (es)
GT (1) GT200900089A (es)
PE (1) PE20081464A1 (es)
UY (1) UY30636A1 (es)
WO (1) WO2008047208A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2381937A2 (en) 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
AU2009352681B2 (en) * 2009-09-17 2014-11-20 Upsher-Smith Laboratories, Llc A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
ES2596359T3 (es) 2009-12-18 2017-01-09 Mdm S.P.A. Formas de dosificación farmacéuticas de tizanidina y su vía de administración
BRPI1103205A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab Ltda Composição farmacêutica oral e uso da composição farmacêutica oral
AU2013252491A1 (en) * 2012-04-27 2014-11-06 Troy Laboratories Pty Ltd Combination meloxicam and xylazine therapy in animals
EA201692426A1 (ru) * 2014-07-21 2017-05-31 Сановель Илач Санайи Ве Тиджарет А.Ш. Комбинации зальтопрофена и миорелаксанта
WO2016193880A1 (en) * 2015-05-29 2016-12-08 Jubilant Generics Limited Immediate release pharmaceutical composition of tizanidine
US20190060287A1 (en) * 2017-08-28 2019-02-28 Adare Pharmaceuticals, Inc. Tizanidine formulations
EP4331588A4 (en) * 2021-04-27 2025-01-15 Animuscure Inc. COMPOSITION FOR THE PREVENTION OR TREATMENT OF MUSCLE DISEASES WITH AN OXICAM-BASED COMPOUND
CN113398096A (zh) * 2021-06-27 2021-09-17 烟台大学 一种含有美洛昔康的长效注射微球及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735369B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US20040204413A1 (en) * 2001-01-26 2004-10-14 Joaquina Faour Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
CA2403670C (en) * 2001-01-31 2010-02-09 Rohm Gmbh & Co. Kg Multiparticulate drug form comprising at least two differently coated pellet forms
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
US8502335B2 (en) 2009-07-29 2013-08-06 Taiwan Semiconductor Manufacturing Company, Ltd. CMOS image sensor big via bonding pad application for AlCu Process

Also Published As

Publication number Publication date
BRPI0718368A2 (pt) 2013-11-12
AR073435A1 (es) 2010-11-10
DE602007012751D1 (de) 2011-04-07
CA2670690C (en) 2014-12-30
ATE499089T1 (de) 2011-03-15
ECSP099348A (es) 2009-06-30
ES2361883T3 (es) 2011-06-24
WO2008047208A1 (es) 2008-04-24
EP2085076A4 (en) 2010-03-17
CA2670690A1 (en) 2008-04-24
US20100166856A1 (en) 2010-07-01
CO6140021A2 (es) 2010-03-19
GT200900089A (es) 2012-01-13
EP2085076B1 (en) 2011-02-23
EP2085076A1 (en) 2009-08-05
CL2007002975A1 (es) 2008-01-04
UY30636A1 (es) 2008-05-02
CR10801A (es) 2009-07-03

Similar Documents

Publication Publication Date Title
PE20081464A1 (es) Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine
Temple et al. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6–12 months) safety of acetaminophen in adult patients with osteoarthritis
CL2021001810A1 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
BR112018003845A2 (pt) auxiliares cirúrgicos com medicamentos afetados por materiais ativadores
WO2011008896A3 (en) Therapeutic methods using controlled delivery devices having zero order kinetics
BRPI0816887A8 (pt) Sistema de administração de droga, métodos de contracepção, para prover concomitantemente contracepção e tratar ou evitar uma doença sexualmente transmitida, e para fabricar o sistema de administração de droga em três-camadas, e, uso do sistema de administração de droga
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
AR097045A2 (es) Sistema terapéutico transdérmico
BRPI0719115B8 (pt) sistema terapêutico transdérmico para administração de buprenorfina à pele
CL2014001029A1 (es) Forma de dosificacion farmaceutica solida oral de liberacion extendida que comprende una formulacion matricial que comprende un agente activo en forma de comprimido o multiparticulado; agente activo es un analgesico opioide; y uso en el tratamiento del dolor. (div. sol. 499-2012).
AR073704A1 (es) Sistema de administracion transdermal de droga para principios activos liquidos que tiene una capa de matriz adhesiva que incluye un ingrediente farmaceutico activo que es seleccionado entre selegilina y rivastigmina
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
BR112013010829A2 (pt) composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma
MX2009011900A (es) Curacion de herida diabetica.
JP2024522910A (ja) コロナ放電処理された経皮送達システム
DE602006016127D1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
BRPI0513598A (pt) formas de dosagem em comprimidos revestidos de liberação entérica
EA201070557A1 (ru) Способы и композиции для замедления набора веса, связанного с применением атипичных антипсихотических препаратов
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
BRPI0607172A2 (pt) método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos
IL292725A (en) Benzazepines are combined for the treatment of Tourette syndrome
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas
JP2025542470A (ja) 経皮送達システムを調製する方法
NZ703464A (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof

Legal Events

Date Code Title Description
FG Grant, registration